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ABSTRACT
We extract entities and relationships related to COVID-19 from a corpus of articles related to Corona virus by employing a novel
entities and relationship model. The entity recognition and relationship discovery models are trained with a multi-task learning
objective on a large annotated corpus. We employ a concept masking paradigm to prevent the evolution of neural networks
functioning as an associative memory and induce right inductive bias guiding the network to make inference using only the
context. We uncover several import subnetworks, highlight important terms and concepts and elucidate several treatment
modalities employed in related ailments in the past.
1 Introduction
The recent outbreak of SARS-CoV-2 has led to a global pandemic with the total number of infections exceeding 6 million
with more than 370000 mortality already. The disease has been code named COVID-19 and had far reaching repercussions the
world over. This article aims to uncover the life science universe of the Corona virus and related ailments by employing some
of the state-of-the-art natural language processing technologies applied to biomedical domain. We took the corpus of about
40000 titles and abstracts released as a part of CORD-19 Open Research Challenge and applied our entity recognition and
relationship discovery models to construct a knowledge graph related to COVID-19. In the process, we uncovered about 40000
entities and 80000 relationships.
This article presents our salient findings and is organized as follows. Section 2 briefly describes our masked entities
model and masked relationship model. Section 3 presents a network analysis of the knowledge network discovered by mining
CORD-19 dataset. The coverage of CORD-19 dataset may be not exhaustive and up-to-date. We took snapshot around April
15, 2020. Nevertheless, the primary aim of this work is to demonstrate the application of artificial intelligence on condensing
unstructured information in the biomedical domain to a sufficiently low entropy state so that some important leads can be
established.
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Figure 1. Full COVID-19 entities and relationship network. – Protein; – Drug; – Disease; – Taxonomy
2 The Entities and Relationship Model
We ran our entity recognition model that was trained on about 1 billion data points that we have built in-house. A corpus of
about 33 million titles and abstracts was tagged for 4 different kinds of entities – protein, drug, disease, and taxonomy. We
employ a novel concept masking paradigm where the term occurrences were replaced by a dummy token. Thus, essentially we
remove the entire vocabulary associated with these entities from our training corpus. This inductive bias guides the model to
make inference using the surrounding context alone and helps us achieve state-of-the-art results on biomedical entity recognition
problem1. We use a transformer architecture2 with the following three joint end-to-end multitask learning objectives: 1) masked
token prediction 2) next sentence prediction 3) entity type prediction. We train the word piece tokenization algorithm on
our in-house corpus to generate a vocabulary set of 30000 word pieces. The network had 8 encoder layers with each layer
composed of self-attention followed by a feedforward network. Positional encodings were used in the beginning. We will have
an elaborate publication on this at a later date1.
We further uncover relationships between the entities by employing our relationship discovery model. The entities are
once again masked to guide the network to make an inference using the context alone. The transformer architecture is once
again used for encoding sentences. We use a novel bilinear attention at the output to model interaction between contextualized
embeddings of the two entities between whom we are trying to establish a relationship3.
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3 The Corona virus network analysis
We present here some of the important subnetworks and concepts uncovered as result of probing of CORD-19 dataset4 by
our neural network models. The findings in the paper are only suggestive and the purpose of this work is to demonstrate the
application of artificial intelligence to uncovering important concepts and relationships in the life sciences domain. We hope to
bring few import leads in sharp focus and help a researcher to narrow down the scope of his search for most important concepts
and relationships. Figure 1 shows the full set of all entities and relationships. We computed Katz centrality measure for each
node in the network. The Katz centrality measure can be understood follows: let A be an n×n adjacency matrix of the network
with the element Ai j being 1 if there is a relationship between node i and node j and zero otherwise. The powers of A such as
kth power Ak is representative of paths between two nodes through intermediaries. The Katz centrality measure for the node i
defined as:
CKatz(i) =
∞
∑
k=1
n
∑
j=1
αk
(
Ak
)
ji
The attenuation factor α is chosen such that it is smaller than the reciprocal of the absolute value of the largest eigenvalue of A.
The top 20 concepts in the literature ranked by the normalized Katz centrality measure5 is shown in Table 1(a). The top ranked
concept is ofcourse coronavirus followed by cytokine. Concepts like spike protein and ACE2 also figure in the top 20. Several
different kinds of viruses such as adenovirus and rotavirus also figure in the top 20 showing the diversity of the CORD-19
dataset. The top proteins are shown in Table 1(b). The adverse cytokine response by the immune system and cytokine storm
(a) Top concepts in the network
Rank Entity Type Centrality Measure
1 coronavirus taxonomy 0.1050
2 cytokine protein 0.0696
3 pneumonia disease 0.0621
4 spike protein protein 0.0595
5 sars disease 0.0580
6 nucleocapsid protein protein 0.0506
7 ace2 protein 0.0450
8 type i ifn drug 0.0401
9 sars-cov taxonomy 0.0399
10 il-6 protein 0.0356
11 asthma disease 0.0347
12 adenovirus taxonomy 0.0344
13 pedv taxonomy 0.0339
14 respiratory syncytial virus taxonomy 0.0319
15 piglet taxonomy 0.0305
16 tnf-α protein 0.0301
17 ifn protein 0.0301
18 influenza virus taxonomy 0.0294
19 sars-cov-2 taxonomy 0.0292
20 covid-19 disease 0.0289
(b) Top proteins in the network
Rank Protein Centrality Measure
1 cytokine 0.0696
2 spike protein 0.0595
3 nucleocapsid protein 0.0506
4 ace2 0.0450
5 il-6 0.0356
6 tnf-α 0.0301
7 ifn 0.0301
8 lectin 0.0285
9 ifn-γ 0.0262
10 il-10 0.0262
11 nf-kb 0.0260
12 envelope protein 0.0252
13 il-8 0.0217
14 membrane protein 0.0207
15 il-1β 0.0194
16 ifn-β 0.0187
17 tlr3 0.0181
18 irf3 0.0177
19 cxcl10 0.0174
20 ifitm3 0.0165
Table 1. Concepts ranked by Katz centrality measure
occurring at a late stage of the ailment is the top mentioned protein concept in the literature. Spike protein which binds so
efficiently to the ACE2 receptor resulting in viral entry is ranked second among all proteins. Spike protein is at the center of
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Figure 2. ACE2 subnetwork – Protein; – Drug; – Disease; – Taxonomy
many therapeutic concepts under evaluation for possible treatments. Surprisingly, nucleocapsid protein or N protein is the
third most important protein concept discussed in the literature. N protein is a multifunctional protein playing a pivotal role
in enhancing the efficiency of viral transcription and assembly. Infact, the machinery related to N protein was proposed as
one of the top therapeutic target in a recent work. It was proposed that targeting of viral translation by interfering with the
eIF4F complex formation or the interactions between viral proteins N, Nsp2, Nsp8, and the transnational machinery may have
therapeutic benefits6.
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Figure 3. TMPRSS2 network
3.1 The ACE2 and Spike protein network
ACE2 protein also finds substantial mentionings in the published literature. We show here the subnetwork of ACE2 in Fig. 2.
The subnetwork has all nodes connected to ACE2 and their interconnections. It is a large network with 367 nodes and 1141
edges. There is a total of 60 drugs, 173 proteins, 90 diseases, and 44 organisms in the ACE2 network. We did path analysis
to uncover more lead compounds in the ACE2 network. We found all the paths between ACE2 and Spike protein with a
maximum of 3 hops between the two nodes. We further impose a condition that all nodes in the path should either be a drug
or a protein. The following drugs or drug like compounds were found in the paths: A291P, Alanine, Arbidol, Chloroquine,
Emodin, Glutathione, HR2P-M2, IL-4, K267N, MAB 1a9, Nitric Oxide, Rabbit Antisera, Sialic acid, SP-10, SP-8, Superoxide,
and TAPI-2. K267E and A291P are actually polymorphism to DDP4 host protease. DDP4 helps the binding of Spike protein to
the host. It was observed that these polymorphism reduce viral replication and thus have a therapeutic effects7. Arbidol is an
antiviral drug that has been reported to block viral entry and replication8. Emodin is another top drug in the ACE2 network that
works by blocking the interaction between ACE2 and Spike protein9. Glutathione works by downregulating ACE210. SP-8 and
SP-10 are peptides that disrupt the binding of Spike protein to ACE211.
While discussing ACE2, it is worth mentioning the role of TMPRSS2 in the pathogenesis. TMPRSS2 is a serine protease
that plays a role in cleaving the spike protein and helps the binding of S protein to ACE2. Figure 3 shows the TMPRSS2
subnetwork. It is a small and yet important subnetwork and is easy to visualize. It has 37 nodes and 95 edges. There are 2
drugs, 20 proteins, 3 diseases, and 12 organisms in the network. Camostat which is a TMPRSS2 inhibitor shows up the network
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and can be used as a drug to block the viral entry. One of the important protein that shows in the network in Fig. 3 is LY6E.
It is an interferon stimulated protein and has been shown to be effective in curbing the entry of SARS-CoV-2 in a couple of
studies12, 13.
3.2 The Viral Protein Network
Figure 4. The subnetwork composed of polymerase, protease, helicase, transferase and related entities
We shift our attention now to the viral target protein network. Figure 4 shows a subnetwork of concepts related to
polymerase, protease, helicase, and transferase. The RNA dependent RNA polymerase (RdRp) is one of the important viral
targets. RdRp is an enzyme that catalyzes the replication of RNA from an RNA template. Several drugs have been proposed
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over the years to inhibit the function of RdRp. Remdesivir has emerged as one of the more promising drugs. Remdesivir
treatment is prohibitively expensive. However, several other drugs have emerged out of our literature mining. In fact, one
of the drugs with a higher centrality measure is Adenosine which is an Adenosine triphoshate analog and can successfully
block the viral replication14. There are few more drugs that have emerged targeting RdRp namely Sofosbuvir, AZT, Tenofovir
Alafenamide, and Alovudine. We also analyzed the 3C-like protease network and 3 experimental drugs named EPDTC,
JMF1586, and JMF1600 emerged.
3.3 The network based drug discovery
Rank Drug Centrality Measure
1 type i ifn 0.0401
2 ifn-α 0.0274
3 ribavirin 0.0222
4 nitric oxide 0.0198
5 sialic acid 0.0180
6 mabs 0.0177
7 il-4 0.0172
8 DCs 0.0172
9 chloroquine 0.0169
10 lipid 0.0153
11 il-2 0.0152
12 ifn- 0.0129
13 zinc 0.0127
14 flavonoid 0.0120
15 quercetin 0.0119
16 atp 0.0112
17 glycyrrhizin 0.0112
18 angiotensin 0.0107
19 emodin 0.0106
20 dexamethasone 0.0103
Table 2. Top drugs in the network
We also ranked all the drugs discovered by their centrality measure. The results are shown in Table 2. The unlikely
candidate here is Type I IFN or Type I Interferon. The second candidate is IFN-α which is related to Type I IFN. The third
candidate is Ribavirin which is very popular anitviral drug effective against many different species of virus. At first, these
results surprised us. However, some of the recent experiments have corroborated our findings. The interferon signalling system
plays a key role in immune system response to virus infestations. It was observed in recent study the SARS-CoV-2 suppresses
the induction of type I interferons while aggravating IL-6 response. These results suggest an important immune imbalance
where low levels of interferons reduces the hosts ability to contain the viral replication, and the activation of IL-6 immune
responses promotes inflammation15. In a recent phase 2 clinical trail, a recombinant type I IFN combined with Ribavirin and
Lopinavir demonstrated good results in curing the COVID-19 ailment compared to administering Ribavirin alone16, 17.
We further tried to uncover the drug used for dealing with SARS-CoV-2 like viruses by interrogating our network for
following concepts: coronavirus, SARS, SARS-CoV, SARS-CoV-2, COVID-19, 2019-ncov, ARDS, MERS, MERS-CoV
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Figure 5. Drug disease network primary set of drugs related to COVID-19
infection, MERS-CoV, RNA virus infections, SARS-CoV mouse lung, SARS-CoV particles, SARS-CoV populations,
SARS-CoV-2 infection, Coronavirus infection, severe acute respiratory syndrome, and, severe acute respiratory syn-
drome coronavirus. We restricted the relationship type as being TREATS. Table 3 in Appendix 5 shows these relations. We
uncovered about 70 such relationships. The hyperlink to the original article can be found in fifth column Reference Id. It is
interesting to note that we discovered the a treatment that have been recently reported to be effective in COVID-19 and have
also been reported earlier in reference to another ailment. A combination treatment with IFN-1b, Lopinavir/Ritonavir, and
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Ribavirin which was recently reported to be successful in phase 2 clinical trial for COVID-1916. We discovered that the same
combination was proposed earlier for MERS (see entry 23)18. Thus, the entries in Table 3 may serve as a ready reference point
to explore many other treatment modalities for COVID-19. The extensive drug-disease network corresponding to Table 3 is
shown in Fig. 5. This subnetwork was formed by taking all the drugs listed in Table 3 and finding all the diseases related to
these drugs.
4 Conclusion
We undertook a comprehensive concept identification and network analysis for COVID-19. We demonstrated the use of a novel
concept recognition and relationship discovery engine that crafts some of the latest advances in natural language processing
into a state-of-the-art solution for biomedical entity recognition and relationship discovery problem. Several new drugs were
uncovered through the studies and many different treatment modalities were brought to the surface. We envision these solutions
to have a wide ranging impact through the length and breadth of drug discovery process spanning all therapeutic areas.
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5 Appendix
Table 3. Drug Disease Release Relationship
Sentence Drug Disease Reference Id
1
However, in our prediction, they may also bind to the
replication complex components of 2019-nCoV with an
inhibitory potency with Kd < 1000 nM. In addition, we
also found that several antiviral agents, such as Kaletra,
could be used for the treatment of 2019-nCoV, although
there is no real-world evidence supporting the prediction.
Kaletra 2019-nCoV 32280433
2
Our observation suggests that AEC2 attenuates LPS-
induced ARDS via the Ang-(1-7) Mas pathway by in-
hibiting ERK/NF-kB activation.
AEC2 ARDS 27302421
3
Methods: PubMed, EMBASE, and three trial Registries
were searched for studies on the use of chloroquine in
patients with COVID-19.
chloroquine COVID-19 32173110
4
The aim of this systematic review was to summarize the ev-
idence regarding chloroquine for the treatment of COVID-
19.
chloroquine COVID-19 32173110
5
Furthermore, integrated analysis predicted that IL-1β and
M-CSF may be novel candidate target genes for inflamma-
tory storm and that TNFSF13, IL-18, IL-2 and IL-4 may
be beneficial for the recovery of COVID-19 patients.
IL-4 COVID-19 32377375
6
Furthermore, integrated analysis predicted that IL-1β and
M-CSF may be novel candidate target genes for inflamma-
tory storm and that TNFSF13, IL-18, IL-2 and IL-4 may
be beneficial for the recovery of COVID-19 patients.
IL-2 COVID-19 32377375
7
An FDA-approved antineoplastic drug, 30 carmofur, has
been identified as an inhibitor that targets COVID-19 virus
M pro .However, its inhibitory mechanism is unknown.
carmofur COVID-19 10.1038
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8This study aims to evaluate the efficacy of hydroxychloro-
quine (HCQ) in the treatment of patients with COVID-
19.Main methods: From February 4 to February 28, 2020,
62 patients suffering from COVID-19 were diagnosed and
admitted to Renmin Hospital of Wuhan University.
HCQ COVID-19 20040758
11
Our study (NCT04252885), designated as ELACOI, was
an exploratory randomized (2:2:1) and controlled one,
exploring the efficacy and safety of lopinavir/ritonavir
(LPV/r) or arbidol monotherapy treating mild/moderate
COVID-19 patients.
lopinavir COVID-19 118529
12
Hydroxychloroquine has recently received Emergency
Use Authorization by the FDA and is currently prescribed
in combination with azithromycin for COVID-19 pneu-
monia.
azithromycin COVID-19 20054551
13
Our data further supports the view that universal BCG vac-
cination has a protective effect on the course of COVID-
19 probably preventing progression to severe disease and
death.
BCG COVID-19 20053272
14
Herein, we examine the effects of Favipiravir (FPV) ver-
sus Lopinavir (LPV)/ritonavir (RTV) for the treatment of
COVID-19.
Lopinavir COVID-19 32346491
15
Herein, we examine the effects of Favipiravir (FPV) ver-
sus Lopinavir (LPV)/ritonavir (RTV) for the treatment of
COVID-19.
Favipiravir COVID-19 32346491
16
Remdesivir (GS-5734TM) is a broad-spectrum antiviral
drug that is now being tested as a potential treatment for
COVID-19 in international, multi-site clinical trials.
Remdesivir COVID-19 32258351
17
We aimed to evaluate the definite efficacy and safety of
corticosteroid in the treatment of severe COVID-19 pneu-
monia.
corticosteroid COVID-19 20032342
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18
We also discussed several putative mechanisms of the
anti-SARS-CoV-2 effects for CVL218 or other PARP1
inhibitors to be involved in the treatment of COVID-19.
CVL218 COVID-19 117314
19
In summary, the PARP1 inhibitor CVL218 discovered by
our data-driven drug repositioning framework can serve as
a potential therapeutic agent for the treatment of COVID-
19.
CVL218 COVID-19 117314
20
Our in silico screening followed by wet-lab validation
indicated that a poly-ADP-ribose polymerase 1 (PARP1)
inhibitor, CVL218, currently in Phase I clinical trial, may
be repurposed to treat COVID-19.
CVL218 COVID-19 117314
21
We aimed to compare arbidol and
lopinavir/ritonavir(LPV/r) treatment for patients
with COVID-19 with LPV/r only.
ritonavir COVID-19 32171872
22
We aimed to compare arbidol and
lopinavir/ritonavir(LPV/r) treatment for patients
with COVID-19 with LPV/r only.
lopinavir COVID-19 32171872
23
The MIRACLE trial (MERS-CoV Infection tReated with
A Combination of Lopinavir/ritonavir and intErferon-
β1b) investigates the efficacy of a combination therapy of
lopinavir/ritonavir and recombinant interferon-β1b pro-
vided with standard supportive care, compared to placebo
provided with standard supportive care, in hospitalized
patients with laboratory-confirmed MERS.
interferon-β1b MERS 29382391
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24
Results from in vitro and animal studies suggest that
a combination of lopinavir/ritonavir and interferon-β1b
(IFN-β1b) may be effective against MERS-CoV. The aim
of this study is to investigate the efficacy of treatment with
a combination of lopinavir/ritonavir and recombinant IFN-
β1b provided with standard supportive care, compared to
treatment with placebo provided with standard supportive
care in patients with laboratory-confirmed MERS requir-
ing hospital admission.
interferon-β1b MERS 29382391
25
Results from in vitro and animal studies suggest that
a combination of lopinavir/ritonavir and interferon-β1b
(IFN-β1b) may be effective against MERS-CoV. The aim
of this study is to investigate the efficacy of treatment with
a combination of lopinavir/ritonavir and recombinant IFN-
β1b provided with standard supportive care, compared to
treatment with placebo provided with standard supportive
care in patients with laboratory-confirmed MERS requir-
ing hospital admission.
IFN-β1b MERS 29382391
26
The data presented here support testing of the efficacy of
remdesivir treatment in the context of a MERS clinical
trial.
remdesivir MERS 32054787
27
In this study, we describe a method for the swift genera-
tion of a humanderived monoclonal antibody, known as
LCA60, as a treatment for MERS infections.
LCA60 MERS 27102927
28
We assessed 3 repurposed drugs with potent in vitro
anti-MERS-CoV activity (mycophenolate mofetil [MMF],
lopinavir/ritonavir, and interferon-β1b) in common mar-
mosets with severe disease resembling MERS in humans.
ritonavir MERS 26198719
29
We assessed 3 repurposed drugs with potent in vitro
anti-MERS-CoV activity (mycophenolate mofetil [MMF],
lopinavir/ritonavir, and interferon-β1b) in common mar-
mosets with severe disease resembling MERS in humans.
mycophenolate
mofetil
MERS 26198719
14/19
30
We aimed to compare ribavirin and interferon alfa-2a treat-
ment for patients with severe MERS-CoV infection with
a supportive therapy only.
interferon alfa-2a
MERS-CoV
infection
25278221
31
We aimed to compare ribavirin and interferon alfa-2a treat-
ment for patients with severe MERS-CoV infection with
a supportive therapy only.
ribavirin
MERS-CoV
infection
25278221
32
These data indicate that saracatinib alone or in combi-
nation with gemcitabine can provide a new therapeutic
option for the treatment of MERS-CoV infection.
saracatinib
MERS-CoV
infection
29785047
33
These data indicate that saracatinib alone or in combi-
nation with gemcitabine can provide a new therapeutic
option for the treatment of MERS-CoV infection.
gemcitabine
MERS-CoV
infection
29785047
34
Having been used extensively in clinical trials and in post-
marketing experience, nitazoxanide is an attractive drug
candidate for treatment of Middle East respiratory syn-
drome.
nitazoxanide
Middle East respi-
ratory syndrome
27095301
35
The objective of this study was to evaluate the effect of rib-
avirin and recombinant interferon (RBV/rIFN) therapy on
the outcomes of critically ill patients with Middle East res-
piratory syndrome (MERS), accounting for time-varying
confounders.
recombinant inter-
feron
Middle East respi-
ratory syndrome
31925415
36
The objective of this study was to evaluate the effect of rib-
avirin and recombinant interferon (RBV/rIFN) therapy on
the outcomes of critically ill patients with Middle East res-
piratory syndrome (MERS), accounting for time-varying
confounders.
ribavirin
Middle East respi-
ratory syndrome
31925415
37
Ribavirin is currently used for the treatment of several
RNA virus infections clinically, so its anti-EV71 efficacy
was evaluated.
Ribavirin
RNA virus infec-
tions
18279075
38
A pilot clinical report showed effectiveness of IFN-α for
the treatment of SARS patients.
IFN-α SARS 15174965
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39
Results from a pilot study to evaluate the clinical efficacy
of IFN-α treatment of SARS patients provided evidence
for IFN-inducible resolution of disease.
IFN-α SARS 16474437
40
We therefore suggest that pegylated IFN-α protects type
1 pneumocytes from SCV infection, and should be con-
sidered a candidate drug for SARS therapy SARS has
recently emerged in the human population as a potentially
fatal respiratory disease.
IFN-α SARS 14981511
41
The efficacy of MAb 201 in the treatment of SARS was
evaluated in golden Syrian hamsters, an animal model
that supports SARS-CoV replication to high levels and
displays severe pathological changes associated with infec-
tion, including pneumonitis and pulmonary consolidation.
MAb 201 SARS 16453264
42
The highest leukocyte and neutrophil counts, lactate de-
hydrogenase, and creatine kinase; positive endexpiratory
pressure; and use of corticosteroids, ribavirin, and intra-
venous immunoglobulin were higher in the SARS group.
ribavirin SARS 190556023
43
Developing high titers of anti-SARS hyperimmune globu-
lin to provide an alternative pathway for emergent future
prevention and treatment of SARS.
anti-SARS hyper-
immune globulin
SARS 16297347
44
Based on these findings, a pilot study to evaluate the poten-
tial clinical benefit and safety of IFN alfacon-1 in SARS
treatment was conducted by our laboratory.
IFN alfacon-1 SARS 7310030
45
Cholesterol depletion by pretreatment of Vero E6 cells
with methyl-b-cyclodextrin (MbCD) inhibited the produc-
tion of SARS-CoV particles released from the infected
cells.
methyl-b-
cyclodextrin
SARS-CoV parti-
cles
17194611
46
Comparison of fullgenome next-generation sequencing of
5-FU treated SARS-CoV populations revealed a 16-fold
increase in the number of mutations within the ExoN2
population as compared to ExoN+.
5-FU
SARS-CoV popu-
lations
23966862
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47
In addition, the results suggest guanosine derivative (IDX-
184), Setrobuvir, and YAK as top seeds for antiviral treat-
ments with high potential to fight the SARS-CoV-2 strain
specifically.
guanosine SARS-CoV-2 32222463
48
In addition, the results suggest guanosine derivative (IDX-
184), Setrobuvir, and YAK as top seeds for antiviral treat-
ments with high potential to fight the SARS-CoV-2 strain
specifically.
IDX-184 SARS-CoV-2 32222463
49
In addition, the results suggest guanosine derivative (IDX-
184), Setrobuvir, and YAK as top seeds for antiviral treat-
ments with high potential to fight the SARS-CoV-2 strain
specifically.
Setrobuvir SARS-CoV-2 32222463
50
In addition, the results suggest guanosine derivative (IDX-
184), Setrobuvir, and YAK as top seeds for antiviral treat-
ments with high potential to fight the SARS-CoV-2 strain
specifically.
YAK SARS-CoV-2 32222463
51
Neutralization test demonstrated that RBD-specific
F(ab’)2 inhibited SARS-CoV-2 with EC50 at 0.07 µg/ml,
showing a potent inhibitory effect on SARS-CoV-2.
RBD-specific
F(ab’)2
SARS-CoV-2 149893
52
Chloroquine has been sporadically used in treating SARS-
CoV-2 infection.
Chloroquine
SARS-CoV-2 in-
fection
32150618
53
Treatment with convalescent plasma for critically ill pa-
tients with SARS-CoV-2 infection
convalescent
plasma
SARS-CoV-2 in-
fection
32243945
54
MAb 1A9 is a broadly neutralizing mAb that prevents
viral entry mediated by the S proteins of human and civet
SARS-CoVs as well as bat SL-CoVs.
MAb 1A9 SARS-CoVs 25019613
55
Among these, the antivirals ledipasvir or velpatasvir are
particularly attractive as therapeutics to combat the new
coronavirus with minimal side effects, commonly fatigue
and headache.
ledipasvir coronavirus 32194944
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56
Among these, the antivirals ledipasvir or velpatasvir are
particularly attractive as therapeutics to combat the new
coronavirus with minimal side effects, commonly fatigue
and headache.
velpatasvir coronavirus 32194944
57
For a random sample of 127 calves, serum zinc concentra-
tions before and after treatment and a fecal antigen ELISA
at diarrhea start and resolution for Escherichia coli K99,
rotavirus, coronavirus, and Cryptosporidium parvum were
performed.
zinc coronavirus 31291305
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Based on our analysis of hepatitis C virus and coron-
avirus replication, and the molecular structures and ac-
tivities of viral inhibitors, we previously reasoned that
the FDA-approved heptatitis C drug EPCLUSA (Sofos-
buvir/Velpatasvir) should inhibit coronaviruses, including
SARS-CoV-2.
EPCLUSA coronaviruses 989186
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Previously, in vitro studies have shown that cyclosporin
(CsA) and FK506 inhibit virus replication in diverse coro-
naviruses.
FK506 coronaviruses 26675666
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Previously, in vitro studies have shown that cyclosporin
(CsA) and FK506 inhibit virus replication in diverse coro-
naviruses.
cyclosporin coronaviruses 26675666
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We investigated the effect of massive doses of corticos-
teroid therapy on bone metabolism using specific biochem-
ical markers of bone metabolism, and the prevalence of os-
teonecrosis in severe acute respiratory syndrome (SARS)
patients at a university teaching hospital in Hong Kong.
corticosteroid
severe acute respi-
ratory syndrome
16753744
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Ribavirin and corticosteroids were used widely as front-
line treatments for severe acute respiratory syndrome;
however, previous evaluations were inconclusive.
Ribavirin
severe acute respi-
ratory syndrome
19958895
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We assessed the effectiveness of ribavirin and corticos-
teroids as the initial treatment for severe acute respiratory
syndrome using propensity score analysis.
ribavirin
severe acute respi-
ratory syndrome
19958895
18/19
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In order to evaluate the efficacy of convalescent plasma
therapy in the treatment of patients with severe acute res-
piratory syndrome (SARS), 80 SARS patients were given
convalescent plasma at Prince of Wales Hospital, Hong
Kong, between 20 March and 26 May 2003.
convalescent
plasma
severe acute respi-
ratory syndrome
15616839
65
A new enzyme-linked immunosorbent assay (ELISA)-
based immunoglobulin G (IgG)-plus-IgM antibody detec-
tion test for severe acute respiratory syndrome (SARS) has
been developed by using a cocktail of four recombinant
polypeptides as the antigen.
(ELISA)-based
immunoglobulin
G
severe acute respi-
ratory syndrome
19038782
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Lianhua-Qingwen capsule (LQC) is a commonly used
Chinese medical preparation to treat viral influenza and
especially played a very important role in the fight against
severe acute respiratory syndrome (SARS) in 2002-2003
in China.
LQC
severe acute respi-
ratory syndrome
25654135
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In this study, we used MRI to observe the lesion size
changes of ONFH induced by corticosteroid administra-
tion in severe acute respiratory syndrome (SARS) patients.
corticosteroid
severe acute respi-
ratory syndrome
19533123
68
Study objective: To investigate the efficacy and safety pro-
files of corticosteroid therapy in severe acute respiratory
syndrome (SARS) patients.
corticosteroid
severe acute respi-
ratory syndrome
16778260
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We found that the butanol fraction of Cinnamomi Cor-
tex (CC/Fr.2) showed moderate inhibitory activity in
wild-type severe acute respiratory syndrome coronavirus
(wtSARS-CoV) and HIV/SARS-CoV S pseudovirus in-
fections.
Cinnamomi Cor-
tex
severe acute respi-
ratory syndrome
coronavirus
19428598
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We recently reported that the nucleoside analogue GS-
5734 (remdesivir) potently inhibits human and zoonotic
CoVs in vitro and in a severe acute respiratory syndrome
coronavirus (SARS-CoV) mouse model.
GS-5734
severe acute respi-
ratory syndrome
coronavirus
7102703
19/19
